Cargando…

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer

PURPOSE: To assess the outcome of radiotherapy (RT) to all PSMA ligand positive metastases for patients with castrate-resistant prostate cancer (mCRPC). PATIENTS AND METHODS: A total of 42 patients developed oligometastatic mCRPC and received PSMA PET-guided RT of all metastases. The main outcome pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Henkenberens, Christoph, Derlin, Thorsten, Bengel, Frank, Ross, Tobias L., Kuczyk, Markus A., Giordano, Frank A., Sarria, Gustavo R., Schmeel, Leonard Christopher, Christiansen, Hans, von Klot, Christoph A. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089391/ https://www.ncbi.nlm.nih.gov/pubmed/33954116 http://dx.doi.org/10.3389/fonc.2021.664225

Ejemplares similares

Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy
por: Henkenberens, Christoph, et al.
Publicado: (2020)

The Prognostic Value of Liquid Biopsies for Benefit of Salvage Radiotherapy in Relapsed Oligometastatic Prostate Cancer
por: Bogdanova, Natalia V., et al.
Publicado: (2022)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Predictive and Prognostic Impact of Blood-Based Inflammatory Biomarkers in Patients with Gastroenteropancreatic Neuroendocrine Tumors Commencing Peptide Receptor Radionuclide Therapy
por: Ohlendorf, Fiona, et al.
Publicado: (2021)

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
por: Oehus, Ann-Kathrin, et al.
Publicado: (2020)

Decision regret in breast cancer patients after adjuvant radiotherapy
por: Köksal, Mümtaz, et al.
Publicado: (2023)

Assessment of γ-H2AX and 53BP1 Foci in Peripheral Blood Lymphocytes to Predict Subclinical Hematotoxicity and Response in Somatostatin Receptor-Targeted Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors
por: Derlin, Thorsten, et al.
Publicado: (2021)

Individual radiosensitivity reflected by γ-H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2022)

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT
por: Werner, Rudolf A., et al.
Publicado: (2019)

Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
por: Mader, Nicolai, et al.
Publicado: (2023)

68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer
por: Kalinauskaite, Goda, et al.
Publicado: (2020)

Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET
por: Sabbagh, Ali, et al.
Publicado: (2022)

Long-term outcomes of SBRT for PSMA PET detected oligometastatic prostate cancer
por: Mohan, Riche, et al.
Publicado: (2023)

Metastasis-Directed Radiotherapy for Oligometastatic Castration-Resistant Prostate Cancer
por: Katano, Atsuto, et al.
Publicado: (2021)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

Vessel Wall Inflammatory Activity as Determined by F-18 Fluorodeoxyglucose PET in Large Vessel Vasculitis Is Attenuated by Immunomodulatory Drugs
por: Sherzay, Romilda, et al.
Publicado: (2021)

Prognostic risk classification for biochemical relapse-free survival in patients with oligorecurrent prostate cancer after [(68)Ga]PSMA-PET-guided metastasis-directed therapy
por: Vogel, Marco M. E., et al.
Publicado: (2020)

Personalized prediction of mode of cardiac death in heart failure using supervised machine learning in the context of cardiac innervation imaging
por: Werner, Rudolf A., et al.
Publicado: (2020)

Combining (68)Ga-PSMA-PET/CT-Directed and Elective Radiation Therapy Improves Outcome in Oligorecurrent Prostate Cancer: A Retrospective Multicenter Study
por: Kirste, Simon, et al.
Publicado: (2021)

PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
por: Deijen, Charlotte L., et al.
Publicado: (2021)

Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer
por: Galgano, Samuel J., et al.
Publicado: (2022)

Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy
por: von Klot, Christoph A., et al.
Publicado: (2017)

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT
por: Ross, M. I., et al.
Publicado: (2020)

Can PSMA PET/CT help in dose-tailoring in post-prostatectomy radiotherapy?
por: Champion, Ambroise, et al.
Publicado: (2023)

PSMA-PET Detection of Unusual Metastases in Castrate-Sensitive Prostate Carcinoma
por: Harris, Nathanial, et al.
Publicado: (2023)

PSMA PET/CT in Castration-Resistant Prostate Cancer: Myth or Reality?
por: Urso, Luca, et al.
Publicado: (2023)

The Role of Ga-68 PSMA PET/CT Scan on Differentiating of Oligometastatic and High Risk Prostate Cancer
por: Erdoğan, Mehmet, et al.
Publicado: (2020)

Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET/CT-guided stereotactic and hypofractionated radiotherapy with elective nodal therapy
por: Gawish, Ahmed, et al.
Publicado: (2022)

Correction to: Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT
por: Ross, M. I., et al.
Publicado: (2020)

Stereotactic ablative body radiotherapy for oligometastatic inguinal lymph node in castrate resistant prostate cancer
por: Goyal, Shikha, et al.
Publicado: (2023)

Dosimetric Comparison of Upfront Boosting With Stereotactic Radiosurgery Versus Intraoperative Radiotherapy for Glioblastoma
por: Sarria, Gustavo R., et al.
Publicado: (2021)

Dosimetric Comparison of Intraoperative Radiotherapy and SRS for Liver Metastases
por: Scafa, Davide, et al.
Publicado: (2021)

(18)F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging
por: Werner, Rudolf A., et al.
Publicado: (2020)

Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer
por: Plichta, Kristin A., et al.
Publicado: (2021)

Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment
por: Derlin, Thorsten, et al.
Publicado: (2021)

PSMA-PET/CT-guided salvage radiotherapy in recurrent or persistent prostate cancer and PSA < 0.2 ng/ml
por: Solomonidou, Nantia, et al.
Publicado: (2023)

A Retrospective Multicenter Analysis of the Incidence of Bone-Only Disease at PSMA PET/CT in Castration Resistant Prostate Cancer Patients
por: Serani, Francesca, et al.
Publicado: (2023)

Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET–Based Salvage Radiotherapy for Recurrent Prostate Cancer
por: Zamboglou, Constantinos, et al.
Publicado: (2023)

Five-Fraction Stereotactic Radiotherapy for Brain Metastases—A Retrospective Analysis
por: Layer, Julian P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_brqmr7286nrdj1pgg88h4i9hhn